Two separate clinical trials investigating HSPC1 inhibitors in NSCLC patients have also identified those with ALK re-arrangement to be more susceptible to HSPC1 inhibitors (Sequist et al. 2010; Socinski et al. 2013). This evidence concerns the gene ALK and non-small cell lung carcinoma.